Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a report issued on Thursday, Benzinga reports. Needham & Company LLC currently has a $222.00 price target on the specialty pharmaceutical company's stock.

Several other equities research analysts have also commented on JAZZ. UBS Group decreased their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a neutral rating on the stock in a research note on Friday, March 1st. Stifel Nicolaus boosted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a buy rating in a research note on Friday, March 15th. Piper Sandler boosted their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. Barclays decreased their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an overweight rating on the stock in a research note on Friday, March 1st. Finally, Robert W. Baird initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an outperform rating and a $160.00 price objective for the company. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $195.25.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded down $1.02 during midday trading on Thursday, reaching $109.29. 1,061,188 shares of the stock were exchanged, compared to its average volume of 614,353. The business's 50-day moving average price is $116.88 and its 200 day moving average price is $121.28. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. Jazz Pharmaceuticals has a twelve month low of $103.01 and a twelve month high of $146.70. The company has a market capitalization of $6.89 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.53 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, sell-side analysts expect that Jazz Pharmaceuticals will post 16.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Philip L. Johnson purchased 12,000 shares of the business's stock in a transaction dated Friday, March 1st. The shares were acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Company insiders own 4.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 203 shares during the last quarter. Cape Investment Advisory Inc. boosted its position in shares of Jazz Pharmaceuticals by 14,600.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after acquiring an additional 292 shares in the last quarter. Covestor Ltd boosted its position in shares of Jazz Pharmaceuticals by 676.5% during the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock valued at $51,000 after acquiring an additional 345 shares in the last quarter. Spire Wealth Management boosted its position in shares of Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 238 shares in the last quarter. Finally, Headinvest LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $56,000. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.